{"entity":{"id":"nct06769113","kind":"trial","name":"A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard Therapy","aka":[],"tldr":"A phase 2 trial of HLX43 in oesophageal cancer, run by Shanghai Henlius Biotech, now recruiting.","summary":"A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard Therapy is a phase 2 interventional study registered as NCT06769113 by Shanghai Henlius Biotech, with 102 participants planned, started 2025-01-26 and due to reach its primary completion in 2026-10-31. Interventions recorded: HLX43.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06769113","url":"https://clinicaltrials.gov/study/NCT06769113"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["esophageal"],"sections":[],"technologies":[],"targets":[],"drugs":["hlx43"],"companies":["henlius"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06769113","phase":"2","setting":"A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Recurrent/Metastatic Esophageal Squamous Cell Carcinoma (ESCC) Failed or Intolerance to Standard First-line Therapy","sponsor":"Shanghai Henlius Biotech","enrolled":102,"outcomes":[]},"route":"/trials/nct06769113/","neighbours":{"cancer":[{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/"}],"drug":[{"id":"hlx43","kind":"drug","name":"HLX43","route":"/drugs/hlx43/"}],"company":[{"id":"henlius","kind":"company","name":"Shanghai Henlius Biotech","route":"/companies/henlius/"}]}}